Clinical Trial Update: A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating 24-hour intraocular pressure lowering and systemic exposure of PF-04217329 in glaucoma and ocular hypertension; trial complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma
• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• PF-04217329

Snippet

Sponsor: Pfizer | Conditions: Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2021-05-03